Telaprevir News and Research

RSS
Novel therapies for HCV treatment can precipitate several changes: Report

Novel therapies for HCV treatment can precipitate several changes: Report

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Combination telaprevir treatment beneficial for retreatment of hepatitis C

Combination telaprevir treatment beneficial for retreatment of hepatitis C

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

New study questions effectiveness of national Silver Alert program

New study questions effectiveness of national Silver Alert program

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Institute of Medicine urges healthcare providers to take steps to battle hepatitis B and C

Institute of Medicine urges healthcare providers to take steps to battle hepatitis B and C

Telaprevir effective in HCV patients

Telaprevir effective in HCV patients

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Supportive data from a preclinical study of SCY-635 to be presented

Supportive data from a preclinical study of SCY-635 to be presented

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association